These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 15967249

  • 1. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 3. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.
    Urol Int; 2008 Mar; 80(1):68-73. PubMed ID: 18204237
    [Abstract] [Full Text] [Related]

  • 4. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L.
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 6. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.
    Br J Cancer; 2002 Sep 23; 87(7):726-8. PubMed ID: 12232754
    [Abstract] [Full Text] [Related]

  • 7. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I, Pinthus Y, Sella BA, Ramon J.
    Harefuah; 2006 Jan 23; 145(1):25-9, 78. PubMed ID: 16450720
    [Abstract] [Full Text] [Related]

  • 8. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D'Eramo G, Silverio FD.
    Prostate; 2004 Mar 01; 58(4):421-8. PubMed ID: 14968443
    [Abstract] [Full Text] [Related]

  • 9. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S, Vincenzo G, Maria AG, Stefano S, Alessandro G, Salvatore M, Vincenzo T, Franco DS.
    Endocr Relat Cancer; 2007 Sep 01; 14(3):625-32. PubMed ID: 17914093
    [Abstract] [Full Text] [Related]

  • 10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 01; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 11. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
    Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E, Touloupidis S.
    Hell J Nucl Med; 2009 Feb 01; 12(3):234-7. PubMed ID: 19936334
    [Abstract] [Full Text] [Related]

  • 12. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE.
    Asian J Androl; 2008 Mar 01; 10(2):207-13. PubMed ID: 18097534
    [Abstract] [Full Text] [Related]

  • 13. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.
    Urologiia; 2004 Mar 01; (1):17-21. PubMed ID: 15022438
    [Abstract] [Full Text] [Related]

  • 14. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
    Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V.
    Urol Int; 2009 Mar 01; 82(2):147-51. PubMed ID: 19321999
    [Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M.
    Cancer Epidemiol Biomarkers Prev; 2005 May 01; 14(5):1270-3. PubMed ID: 15894684
    [Abstract] [Full Text] [Related]

  • 16. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M, Kovacic K, Kraljic I, Tarle M.
    Anticancer Res; 2001 May 01; 21(2B):1475-9. PubMed ID: 11396235
    [Abstract] [Full Text] [Related]

  • 17. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T.
    Eur Urol; 2005 Aug 01; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [Abstract] [Full Text] [Related]

  • 18. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 19. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F.
    Prostate; 2003 May 15; 55(3):168-79. PubMed ID: 12692782
    [Abstract] [Full Text] [Related]

  • 20. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
    Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA.
    Cancer Epidemiol Biomarkers Prev; 2003 Dec 15; 12(12):1429-37. PubMed ID: 14693733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.